Advertisement

Cancer and Metastasis Reviews

, Volume 9, Issue 3, pp 203–226 | Cite as

Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis

  • Israel Vlodavsky
  • Gil Korner
  • Rivka Ishai-Michaeli
  • Pnina Bashkin
  • Rachel Bar-Shavit
  • Zvi Fuks
Article

Summary

Neoplastic cells require an appropriate pericellular environment and new formation of stroma and blood vessels in order to constitute a soilid tumor. Tumor progression also involves degradation of various extracellular matrix (ECM) constituents. In this review we have focused on the possible involvement of ECM-resident growth factors and enzymes in neovascularization and cell invasion. We demonstrate that the pluripotent angiogenic factor, basic fibroblast growth factor (bFGF) is an ECM component required for supporting cell proliferation and differentiation. Basic FGF has been identified in the subendothelial ECM producedin vitro and in basement membranes of the cornea and blood vesselsin vivo. Despite the ubiquitous presence of bFGF in normal tissues, endothelial cell (EC) proliferation in these tissues is usually very low, suggesting that bFGF is somehow sequestered from its site of action. Our results indicate that bFGF is bound to heparan sulfate (HS) in the ECM and is released in an active form when the ECM-HS is degraded by cellular heparanase. We propose that restriction of bFGF bioavailability by binding to ECM and local regulation of its release, provides a novel mechanism for regulation of capillary blood vessel growth in normal and pathological situations. Heparanase activity correlates with the metastatic potential of various tumor cells and heparanase inhibiting molecules markedly reduce the incidence of lung metastasis in experimental animals. Heparanase may therefore participate in both tumor cell invasion and angiogenesis through degradation of the ECM-HS and mobilization of ECM-resident EC growth factors. The subendothelial ECM contains also tissue type- and urokinase type- plasminogen activators (PA), as well as PA inhibitor which may regulate cell invasion and tissue remodeling. Heparanase and the ECM-resident PA participate synergistically in sequential degradation of HS-proteoglycans in the ECM. These results together with similar observations on the properties of other ECM-immobilized enzymes and growth factors, suggest that the ECM provides a storage depot for biologically active molecules which are thereby stabilized and protected. This may allow a more localized, regulated and persistent mode of action, as compared to the same molecules in a fluid phase.

Key words

angiogenesis metastasis extracellular matrix basic fibroblast growth factor heparanase endothelial cells 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Grobstein C: Mechanism of organogenetic tissue interaction. Natl Cancer Inst Monograph 26: 279–299, 1967Google Scholar
  2. 2.
    Hay ED: Extracellular matrix. J Cell Biol 91: 2055s-2235s, 1981Google Scholar
  3. 3.
    Wessels NK: Tissue interaction and development. Benjamin WA, Melno Park CA, 1977Google Scholar
  4. 4.
    Reddi AH, Anderson WA: Collagenous bone matrix induced endochondral ossification and hemopoiesis. J Cell Biol 69: 557–572, 1976Google Scholar
  5. 5.
    Bernfield MR, Banerjee SD, Cohn RH: Dependence of salivary epithelial morphology and branching morphogenesis upon acid mucopolysaccharide protein of the epithelial surface. J Cell Biol 52: 674–689, 1972Google Scholar
  6. 6.
    Dodson JW: On the nature of tissue interactions in embryonic skin. Exp Cell Res 31: 233–240, 1963Google Scholar
  7. 7.
    Wessels NK: Substrate and nutrient effects upon epidermal basal cell differentiation and proliferation. Proc Natl Acad Sci USA 52: 252–259, 1964Google Scholar
  8. 8.
    Hay ED: Development of the vertebrate cornea. Int Rev Cytol 63: 263–322, 1980Google Scholar
  9. 9.
    Barsky SH, Rao CN, Grotendorst GR, Liotta LA: Increased content of type V collagen in desmoplasia of human breast carcinoma. Am J Pathol 108: 276–282, 1982Google Scholar
  10. 10.
    Gospodarowicz D, Tauber J-P: Growth factors and extracellular matrix. Endocr Rev 1: 201–227, 1980Google Scholar
  11. 11.
    Kleinman HK, Klebe FJ, Martin GR: Role of collagenous matrices in the adhesion and growth of cells. J Cell Biol 88: 473–485, 1981Google Scholar
  12. 12.
    Hall HG, Farson DA, Bissell MJ: Lumen formation by epithelial cell lines in response to collagen overlay: a morphogenetic model in culture. Proc Natl Acad Sci USA 76: 4672–4676, 1982Google Scholar
  13. 13.
    Enat R, Jefferson DM, Ruiz-Opazo N, Gatmaitan Z, Leinwand L, Reid LM: Hepatocyte proliferationin vitro: its dependence on the use of serum free, hormonally defined medium and substrate of extracellular matrix. Proc Natl Acad Sci USA 81: 1411–1415, 1984Google Scholar
  14. 14.
    Gospodarowicz D, Delgado D, Vlodavsky I: Permissive effect of the extracellular matrix on cell proliferationin vitro. Proc Natl Acad Sci USA 77: 4094–4098, 1980Google Scholar
  15. 15.
    Vlodavsky I, Liu GM, Gospodarwicz D: Morphological appearance, growth behavior and migratory activity of human tumor cells maintained on extracellular matrix vs plastic. Cell 19: 607–616, 1980Google Scholar
  16. 16.
    Gospodarowicz D, Vlodavsky I, Savion N: The extracellular matrix and the control of proliferation of vascular endothelial and vascular smooth muscle cells. J Supramol Struc 13: 339–372, 1980Google Scholar
  17. 17.
    Vlodavsky I, Levi A, Lax I, Schlessinger J, Fuks Z: Induction of cell attachment and morphological differentiation in a pheochromocytoma cell line and embryonal sensory cells by the extracellular matrix. Develop Biol 93: 285–300, 1982Google Scholar
  18. 18.
    Barsky SH, Siegal G, Janotta F, Liotta LA: Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab Invest 49: 140–148, 1983Google Scholar
  19. 19.
    Gospodarowicz D, Lepine J, Massoglia S, Wood I: Comparison of the ability of basement membranes produced by corneal endothelial and mouse-derived endodermal PF-HR-9 cells to support the proliferation and differentiation of bovine kidney tubule epithelial cellsin vitro. J Cell Biol 99: 947–961, 1984Google Scholar
  20. 20.
    Gospodarowicz D, Gonzales R, Fujii DK: Are factors originating from serum, plasma or cultured cells involved in the growth promoting effect of the extracellular matrix produced by cultured bovine corneal endothelial cells. J Cell Physiol 114: 191–202, 1983Google Scholar
  21. 21.
    Gospodarowicz D, Ill CR: Do plasma and serum have different abilities to promote cell growth? Proc Natl Acad Sci USA 77: 2726–2730, 1980Google Scholar
  22. 22.
    Tauber J-P, Cheng J, Massoglia S, Gospodarowicz D: High density lipoprotein and the growth of vascular endothelial cells in serum free medium. In vitro 17: 519–530, 1981Google Scholar
  23. 23.
    Fridman R, Alon Y, Doljansky R, Fuks Z, Vlodavsky I: Cell interaction with the extracellular matrices produced by endothelial cells and fibroblasts. Expt Cell Res 158: 462–476, 1985Google Scholar
  24. 24.
    Ruoslahti E, Pierschbacher MD: Arg-Gly-Asp: A versatile cell recognition signal. Cell 44: 517–518, 1986Google Scholar
  25. 25.
    Hynes RO: Integrins: A family of cell surface receptors. Cell 48: 549–554, 1987Google Scholar
  26. 26.
    Srivastava A, Laidler P, Hughes LE, Woodcock J, Shedden EJ: Neovascularization in human cutaneous melanoma: A quantitative morphological and doppler ultra sound study. Eur J Cancer Clin Oncol 22: 1205–1209, 1986Google Scholar
  27. 27.
    Folkman J, Klagsbrun M: Angiogenic factors: Science 235: 442–447, 1987Google Scholar
  28. 28.
    Burgess WH, Maciag T: The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 58: 575–606, 1989Google Scholar
  29. 29.
    Gospodarowicz D, Ferrara N, Schweigerer L, Neufeld G: Structural characterization and biological functions of fibroblast growth factor. Endocrine Rev 8: 95–114, 1987Google Scholar
  30. 30.
    Lobb RR: Clinical applications of heparin-binding growth factors. Eur J Clin Invest 18: 321–336, 1988Google Scholar
  31. 31.
    Thomas KA: Transforming potential of fibroblast growth factor genes. TIBS 24: 327–328, 1988Google Scholar
  32. 32.
    Rifkin DB, Moscatelli D: Recent developments in the cell biology of basic fibroblast growth factor. J Cell Biol 109: 1–6, 1989Google Scholar
  33. 33.
    Moscatelli D, Presta M, Rifkin DB: Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis, and migration. Proc Natl Acad Sci USA 83: 2091–2095, 1986Google Scholar
  34. 34.
    Voldavsky I, Folkman J, Sullivan R, Fridman R, Ishai-Michaelli R, Sasse J, Klagsbrun M: Endothelial cell-derived basic fibroblast growth factor: Synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci USA 84: 2292–2296, 1987Google Scholar
  35. 35.
    Baird A, Ling N: Fibroblast growth factors are present in the extracellular matrix produced by endothelial cellsin vitro: Implications for a role of heparinase-like enzymes in the neovascular response. Biochem Biophys Res Commun 142: 428–435, 1987Google Scholar
  36. 36.
    Weiner HL, Swain JL: Acidic fibroblast growth factor mRNA is expressed by cardiac myocytes in culture and the protein is localized to the extracellular matrix. Proc Natl Acad USA 86: 2683–2687, 1989Google Scholar
  37. 37.
    Gospodarowicz D, Cheng J: Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 128: 475–484, 1986Google Scholar
  38. 38.
    Saksela O, Moscatelli D, Sommer A, Rifkin DB: Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 107: 743–751Google Scholar
  39. 39.
    Denekamp J: Progress in applied microcirculation. In: Hammerson F, Hudlicka O (ed), Karger, Basel, 1984, pp 28–38Google Scholar
  40. 40.
    Baird A, Walicke PA: Fibroblast growth factors: British Medical Bulletin 45: 438–452, 1989Google Scholar
  41. 41.
    Vlodavsky I, Fridman R, Sullivan R, Sasse J, Klagsbrun M: Aortic endothelial cells synthesize basic fibroblast growth factor which remains cell associated and platelet-derived growth factor which is secreted. J Cell Physiol 131: 402–408, 1987Google Scholar
  42. 42.
    Abraham JA, Mergia A, Whang JL, Tumolo A, Friedman J, Hjerrild KA, Gospodarowicz D, Fiddes C: Nucleotide sequence of a bovine clone encoding the angiogenic protein basic fibroblast growth factor. Science 233: 545–548, 1986Google Scholar
  43. 43.
    Fridman R, Ovadia H, Fuks Z, Vlodavsky I: Differential structural requirements for the induction of cell attachment, proliferation and differentiation by the extracellular matrix. Exptl Cell Res 157: 181–194, 1985Google Scholar
  44. 44.
    Thornton SC, Mueller SN, Levine EM: Human endothelial cells: use of heparin in cloning and long-term serial cultivation. Science 222: 623–625, 1983Google Scholar
  45. 45.
    Robinson J, Gospodarowicz D: Characterization of glycosaminoglycans synthesized by the cultured bovine corneal endothelial cells. J Cell Physiol 117: 368–376, 1983Google Scholar
  46. 46.
    Schweigerer L, Neufeld G, Fridman J, Abraham J, Fiddes JC, Gospodarowicz D: Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature 325: 257–259, 1987Google Scholar
  47. 47.
    Moscatelli D, Presta M, Joseph-Silverstein J, and Rifkin DB: Both normal and tumor cells produce basic fibroblast growth factor. J Cell Physiol 129: 273–281, 1986Google Scholar
  48. 48.
    Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I: A heparin-binding angiogenic protein-basic fibroblast growth factor-is stored within basement membrane. Am J Pathol 130: 393–400, 1988Google Scholar
  49. 49.
    Hanneken A, Lutty GA, McLeod DS, Robey F, Harvey AK, and Hjelmeland LM: Localization of basic fibroblast growth factor to the developing capillaries of bovine retina. J Cell Physiol 138: 115–120, 1989Google Scholar
  50. 50.
    Silverstein J, Consigli SA, Lyser KM, and VerPault C: Basic fibroblast growth factor in the chick embryo: immunolocalization to striated muscle cells and their precursors. J Cell Biol 108: 2459–2466, 1989Google Scholar
  51. 51.
    Kardami E, and Fandrich ER: Basic fibroblast growth factor in atria and ventricles of the vertebrate heart. J Cell Biol 109: 1865–1875, 1989Google Scholar
  52. 52.
    Cardon-Cardo C, Vlodavsky I, Haimovitz-Friedman A, Hicklin D, Fuks Z: Expression of basic fibroblast growth factor in normal human tissues. Lab Invest. in press, 1990Google Scholar
  53. 53.
    Kurokawa M, Doctrow S, Klagsbrun M: Neutralizing antibodies inhibit the binding of basic fibroblast growth factor to its receptor but not to heparin. J Biol Chem 264: 7686–7691, 1989Google Scholar
  54. 54.
    Rogelj S, Klagsbrun M, Atzmon R, Kurokawa M, Haimovitz A, Fuks Z, Vlodavsky I: Basic fibroblast growth factor is an extracellular matrix component required for supporting the proliferation of vascular endothelial cells and the differentiation of PC12 cells. J Cell Biol 109: 824–831, 1989Google Scholar
  55. 55.
    Rogelj S, Weinberg RA, Fanning P, Klagsbrun M: Basic fibroblast growth factor fused to a signal peptide transforms cells. Nature 331: 173–175, 1988Google Scholar
  56. 56.
    Feige J-J, Bradey JD, Fryburg K, Farris J, Cousens LC, Barr PJ, Baird A: Differential effects of heparin, fibronectin and laminin on the phosphorylation of basic fibroblast growth factor by protein kinase C and the catalytic subunit of protein kinase A. J Cell Biol 109: 3105–3114, 1989Google Scholar
  57. 57.
    Bashkin P, Klagsbrun M, Doctrow S, Svahn C-M, Folkman J, Vlodavsky I: Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparanase and heparin-like molecules. Biochemistry 28: 1737–1743, 1989Google Scholar
  58. 58.
    Moscatelli D: High and low affinity binding sites for basic fibroblast growth factor on cultured cells: absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells. J Cell Physiol 131: 123–130, 1987Google Scholar
  59. 59.
    Presta M, Maier JAM, Rusnati M, Ragnotti G: Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. J Cell Physiol 140: 68–74, 1989Google Scholar
  60. 60.
    Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y, Schirrmacher V: Lymphoma cell mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: Relationship to tumor cell metastasis. Cancer Res 43: 2704–2711, 1983Google Scholar
  61. 61.
    Nakajima M, Irimura T, Nicolson GL: Heparanases and tumor metastasis. J Cell Biochem 36: 157–167, 1988Google Scholar
  62. 62.
    Ishai-Michaeli R, Eldor A, Vlodavsky I: Heparanase activity expressed by platelets, neutrophils and lymphoma cells releases active fibroblast growth factor from extracellular matrix. Cell Reg. in press, 1990Google Scholar
  63. 63.
    Yahalom J, Eldor A, Fuks Z and Vlodavsky I: Degradation of sulfated proteoglycans in the subendothelial extracellular matrix by human platelet heparitinase. J Clin Invest 74: 1842–1849, 1984.Google Scholar
  64. 64.
    matzner Y, Bar-Ner M, Yahalom J, Ishay-Michaeli R, Fuks Z, and Vlodavsky I: Degradation of heparan sulfate in the subendothelial basement membrane by a readily released heparanase from human neutrophils. J Clin Invest 76: 1306–1313, 1985Google Scholar
  65. 65.
    Savion N, Fuks Z, and Vlodavsky I: Interaction of T lymphocytes and macrophages with cultured vascular endothelial cells: Attachment, invasion and subsequent degradation of the subendothelial extracellular matrix. J Cell Physiol 118: 169–176, 1984Google Scholar
  66. 66.
    Naparstek Y, Cohen IR, Fuks Z, and Vlodavsky I: Activated T lymphocytes produce a matrix-degrading heparan sulfate endoglycosidase. Nature 310: 241–243, 1984Google Scholar
  67. 67.
    Baird A, Mormede P, Bohlen P: Immunoreactive fibroblast growth factor in cells of peritoneal exudate suggests its identity with macrophage derived growth factor. Biochem Biophys Res Commun 126: 358–363, 1985Google Scholar
  68. 68.
    Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, Usuki K, Takahu F, Risau W Heldin C-H: Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 338: 557–561, 1989Google Scholar
  69. 69.
    Bashkin P, Razin E, Eldor A, Vlodavsky I: Degranulating mast cells secrete an endoglycosidase that degrades heparan sulfate in subendothelial extracellular matrix. Blood 75: 2204–2212, 1990Google Scholar
  70. 70.
    Kessler DA, Langer RS, Pless NA, Folkman J: Mast cell and tumor angiogenesis. Int J Cancer 18: 703–709, 1976Google Scholar
  71. 71.
    Flaumenhaft R, Moscatelli D, Saksela O, Rifkin DB: Role of extracellular matrix in the action of bFGF: Matrix as a source of growth factor for long-term stimulation of plasminogen activator and DNA synthesis. J Cell Physiol 140: 75–81, 1989Google Scholar
  72. 72.
    Ishihara M, Fedarko NS, Conard HE: Involvement of phosphatidylinositol and insulin in the coordinate regulation of proteoheparan sulfate metabolism and hepatocyte growth. J Biol Chem 262: 4708–4716, 1987Google Scholar
  73. 73.
    Witte L, Fuks Z, Haimovitz-Friedman A, Vlodavsky I, Goodman DS, Eldor A: Effects of irradiation on the release of growth factors from cultured bovine, porcine, and human endothelial cells. Cancer Res 49: 5066–5072, 1989Google Scholar
  74. 74.
    Liotta LA, Rao CN, Barsky SH: Tumor invasion and the extracellular matrix. Lab Invest 49: 639–649, 1983Google Scholar
  75. 75.
    Jones PA, DeClerck YA: Extracellular matrix destruction by invasive tumor cells. Cancer Met Rev 1: 289–317, 1982Google Scholar
  76. 76.
    Laterra J, Silbert JE, Culp LA: Cell surface heparan sulfate mediates some adhesive responses to glycosami-noglycan-binding matrices, including fibronectin. J Cell Biol 96: 112–120, 1983Google Scholar
  77. 77.
    Vlodavsky I, Ishai-Michaeli R, Bar-Ner M, Fridman R, Horowitz AT, Fuks Z, and Biran S: Involvement of heparanase in tumor metastasis and angiogenesis. Is J Med 24: 464–470, 1988Google Scholar
  78. 78.
    Parish CR, Coombe DR, Jacobsen KB, and Underwood PA: Evidence that sulphated polysaccharides inhibit tumor metastasis by blocking tumor cell-derived heparanase. Int J Cancer 40: 511–517, 1987Google Scholar
  79. 79.
    Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139–266, 1985Google Scholar
  80. 80.
    Salonen E-M, Zitting A, Vaheri A: Laminin interacts with plasminogen and its tissue-type activator. FEBS 172: 29–32, 1989Google Scholar
  81. 81.
    Quigley JP, Gold LI, Schirimmer R, Sullivan L: Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells. Proc Natl Acad Sci USA 84: 2776–2780, 1987Google Scholar
  82. 82.
    Laiho M, Keski-Oja J: Growth factors in the regulation of pericellular proteolysis: A review. Cancer Res 49: 2533–2553, 1989Google Scholar
  83. 83.
    Quigley JP, Sullivan LM: An anticatalytic monoclonal antibody to avian plasminogen activator: its effect on behavior of RSV-transformed chick fibroblasts. Cell 45: 905–915, 1986Google Scholar
  84. 84.
    Bar-Ner M, Mayer M, Schirrmacher V, Vlodavsky I: Involvement of both heparanase and plasminogen activator in lymphoma cell mediated degradation of heparan sulfate in the subendothelial extracellular matrix. J Cell Physiol 128: 299–307, 1986Google Scholar
  85. 85.
    Korner G, Bar-Ner M, Bjornsson TD, Kuo B-S, Vlodavsky I: Extracellular matrix produced by cultured bovine corneal and aortic endothelial cells contains active tissue type - and urokinase type — plasminogen activators. Biochem J. SubmittedGoogle Scholar
  86. 86.
    McGuire PG, Seeds NW: The interaction of plasminogen activator with a reconstituted basement membrane matrix and extracellular macromolecules produced by cultured epithelial cells. J Cell Biochem 40: 215–227, 1989Google Scholar
  87. 87.
    Chen J-M, Chen W-T: Fibronectin degrading proteases from the membranes of transformed Cells. Cell 48: 193–203, 1987Google Scholar
  88. 88.
    Pollanen J, Saksela O, Salonen E-M, Andreasen P, Nielsen L, Dano K, Vaheri A: Distinct localization of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol 104: 1085–1096, 1987Google Scholar
  89. 89.
    Liotta L, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S: Effect of plasminogen activator (urokinase), plasmin and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 41: 2649–4636, 1981Google Scholar
  90. 90.
    Skriver L, Larsson L-I, Kielberg V, Nielsen LS, Andresen PB, Kristensen P, Dano K: Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J Cell Biol 99: 752–757, 1984Google Scholar
  91. 91.
    Ossowski L, Reich E: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35: 611–619, 1983Google Scholar
  92. 92.
    Ossowski L: Plasminogen activator dependent pathway in the dissemination of human tumor cells in the chick embryo. Cell 52: 321–328, 1988Google Scholar
  93. 93.
    Mimuro J, Schleef R, Loskutoff DJ: Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood 70: 721–728, 1987Google Scholar
  94. 94.
    Knudsen BS, Harpel PC, Nachman RL: Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells. J Clin Invest 80: 1082–1089, 1987Google Scholar
  95. 95.
    Schleef RR, Loskutoff DJ: Fibrinolytic system of vascular endothelial cells: Role of plasminogen activator inhibitors. Haemostasis 18: 328–341, 1988Google Scholar
  96. 96.
    Salonen E-M, Vaheri A, Pollanen J, Stephens R, Andreasen P, Mayer M, Dano K, Galit J, Ruoslahti E: Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J Biol Chem 264: 6339–6343, 1989Google Scholar
  97. 97.
    Saksela O, Moscatelli D, Rifkin DB: The opposing effects of basic fibroblast growth factor and transforming growth factor-on regulation of plasminogen activator activity in capillary endothelial cells. J Cell Biol 105: 957–963, 1987Google Scholar
  98. 98.
    Ingber DE, Folkman J: Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesisin vitro: role of extracellular matrix. J Cell Biol 109: 317–330, 1989Google Scholar
  99. 99.
    Gordon MY, Riley GP, Watt SM, Greaves MF: Compart-mentalization of a haematopoietic growth factor (GM, CSF) by glycosaminoglycans in the bone marrow microen-vironment. Nature 326: 403–405, 1987Google Scholar
  100. 100.
    Roberts R, Gallagher J, Spooncer S, Allen TD, Bloomfield F, Dexter TM: Heparan sulphate bound growth factors: a mechanism for stromal cell mediated haemopoiesis. Nature 332: 376–378, 1988Google Scholar
  101. 101.
    Massague J, Cheifetz C: Transforming growth factor-β (TGFβ) receptor proteoglycan. Cell surface expression and ligand binding in the absence of glycosaminoglycan chains. J Biol Chem 264: 12025–12028, 1989Google Scholar
  102. 102.
    Andres JL, Stanley K, Cheifetz S, Massague J: Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-β. J Cell Biol 109: 3137–3145, 1989Google Scholar
  103. 103.
    Sporn MB, Roberts AB, Wakefield LM, deCombrugghe E: Some recent advances in the chemistry and biology of transforming growth factor-β. J Cell Biol 105: 1039–1045, 1987Google Scholar
  104. 104.
    Sampath TK, Muthukumaran M, Reddi AH: Isolation of osteogenin, an extracellular matrix associated bone inductive protein, by heparin affinity chromatography. Proc Natl Acad Sci USA 84: 7109–7113, 1987Google Scholar
  105. 105.
    Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M: Growth factors in bone matrix. Isolation and multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem 261: 12665–12674, 1986Google Scholar
  106. 106.
    Panayotou G, End P, Aumailley M, Timpl R, Engel J: Domains of laminin with growth-factor activity. Cell 56: 93–101, 1989Google Scholar
  107. 107.
    Bar-Shavit R, Eldor A, Vlodavsky I: Binding of thrombin to subendothelial extracellular matrix: protection and expression of functional properties. J Clin Invest 84: 1096–1104, 1989Google Scholar
  108. 108.
    Knudsen BS, Silverstein RL, Leung LLK, Harpel PC, Nachman RL: Binding of plasminogen to extracellular matrix. J Biol Chem 261: 10765–10771, 1986Google Scholar
  109. 109.
    Chajek-Shaul T, Friedman G, Bengtsson-Olivecrona A, Vlodavsky I, Bar-Shavit R: Interaction of lipoprotein lipase with subendothelial extracellular matrix. Biochim Biophys Acta 1042: 168–175, 1990Google Scholar
  110. 110.
    Paget S: The distribution of secondary growth of cancer of the breast. Lancet 1: 571–579, 1989Google Scholar
  111. 111.
    Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM, Fidler IJ: Influence of organ environment on the growth, selection and metastasis of human colon carcinoma cells in nude mice. Cancer Res 48: 6863–6871, 1988Google Scholar
  112. 112.
    Gavanaugh PG, Nicolson GL: Purification and some properties of lung-derived growth factor that differentially stimulates the growth of tumor cells metastatic to the lung. Cancer Res 49: 3928–3933, 1989Google Scholar
  113. 113.
    Dotto GP, Moellmann G, Ghosh S, Edwards M, Halaban R: Transformation of murine melanocytes by bFGF cDNA and oncogens and selective suppression of the transformed phenotype in a reconstituted cutaneous environment. J Cell Biol 109: 3115–3128, 1989Google Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • Israel Vlodavsky
    • 1
  • Gil Korner
    • 1
  • Rivka Ishai-Michaeli
    • 1
  • Pnina Bashkin
    • 1
  • Rachel Bar-Shavit
    • 1
  • Zvi Fuks
    • 2
  1. 1.Department of OncologyHadassah-Hebrew University HospitalJerusalemIsrael
  2. 2.Department of Radiation OncologyMemorial Sloan-kettering Cancer CenterNew YorkUSA

Personalised recommendations